Investment Topics

Auto Added by WPeMatico

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity Read Post »

Scroll to Top